32-PK-DDIs.txt	midazolam	fluconazole	1	1	true	negative	The effect of fluconazole on the pharmacokinetics and pharmacodynamics of midazolam was examined in a randomized, cross-over study in 12 volunteers.
197-PK-DDIs.txt	lamivudine	ribavirin	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	lamivudine	stavudine	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	lamivudine	zidovudine	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	phenytoin	phenytoin	46	46	true	negative	However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.
197-PK-DDIs.txt	phenytoin	zidovudine	46	46	true	negative	However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.
197-PK-DDIs.txt	ribavirin	lamivudine	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	ribavirin	phenytoin	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	ribavirin	ribavirin	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	ribavirin	stavudine	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	ribavirin	zidovudine	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	stavudine	ribavirin	49	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	stavudine	zidovudine	49	47	true	negative	Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.  Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.  However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].
197-PK-DDIs.txt	triphosphate	lamivudine	51	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].  12.4 Microbiology    Mechanism of Action:  Zidovudine is a synthetic nucleoside analogue.  Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP).
197-PK-DDIs.txt	triphosphate	ribavirin	51	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].  12.4 Microbiology    Mechanism of Action:  Zidovudine is a synthetic nucleoside analogue.  Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP).
197-PK-DDIs.txt	triphosphate	stavudine	51	49	true	negative	However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].  12.4 Microbiology    Mechanism of Action:  Zidovudine is a synthetic nucleoside analogue.  Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP).
197-PK-DDIs.txt	zidovudine	3'-amino-3'-deoxythymidine	8	10	true	positive	GZDV AUC is about 3-fold greater than the zidovudine AUC.  Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration.  A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine.
33-PK-DDIs.txt	fluconazole	azithromycin	1	1	true	negative	An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 800 mg oral dose of fluconazole on the pharmacokinetics of a single 1200 mg oral dose of azithromycin as well as the effects of azithromycin on the pharmacokinetics of fluconazole.
124-PK-DDIs.txt	propafenone	propranolol	1	1	true	positive	The AUC of propafenone is increased by more than 200% by co-administration of propranolol.
96-PK-DDIs.txt	alprazolam	fluvoxamine	1	1	true	positive	Coadministration of fluvoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71%, and decreased measured psychomotor performance.
72-PK-DDIs.txt	rifampin	oxycodone	10	10	true	positive	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.
174-PK-DDIs.txt	rifampin	tacrolimus	1	1	true	positive	In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (14±6% vs. 7±3%) was observed with concomitant rifampin administration (600 mg).
192-PK-DDIs.txt	fluvastatin	erythromycin	1	1	true	negative	Erythromycin:    Erythromycin (500 mg, single dose) did not affect steady-state plasma levels of fluvastatin (40 mg daily).
156-PK-DDIs.txt	aliskiren	aliskiren	1	1	true	positive	7  DRUG INTERACTIONS    7.1 Effects of Other Drugs on Aliskiren    Based on in vitro studies, aliskiren is metabolized by CYP 3A4.
156-PK-DDIs.txt	aliskiren	atenolol	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	aliskiren	celecoxib	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	aliskiren	digoxin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	aliskiren	hydrochlorothiazide	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	aliskiren	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.
156-PK-DDIs.txt	aliskiren	lovastatin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	aliskiren	ramipril	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	aliskiren	warfarin	12	14	true	negative	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.  However, no dosage adjustment is necessary.  Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
156-PK-DDIs.txt	amlodipine	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	atenolol	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	atorvastatin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	celecoxib	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	cyclosporine	cyclosporine	10	10	true	positive	Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.
156-PK-DDIs.txt	digoxin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	furosemide	aliskiren	17	15	true	positive	7.2 Effects of Aliskiren on Other Drugs    Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.  Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.  Patients receiving furosemide could find its effect diminished after starting aliskiren.
156-PK-DDIs.txt	irbesartan	irbesartan	2	2	true	positive	Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
156-PK-DDIs.txt	itraconazole	aliskiren	8	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.
156-PK-DDIs.txt	itraconazole	itraconazole	8	8	true	positive	Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.
156-PK-DDIs.txt	ketoconazole	aliskiren	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
156-PK-DDIs.txt	ketoconazole	atorvastatin	6	5	true	positive	Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.  Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
156-PK-DDIs.txt	ketoconazole	itraconazole	6	8	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.  A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.  Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.
156-PK-DDIs.txt	ketoconazole	ketoconazole	6	6	true	positive	Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
156-PK-DDIs.txt	lovastatin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	metformin	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	ramipril	aliskiren	18	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
156-PK-DDIs.txt	verapamil	verapamil	12	12	true	positive	Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.
156-PK-DDIs.txt	warfarin	aliskiren	19	17	true	negative	Patients receiving furosemide could find its effect diminished after starting aliskiren.  Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.  Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.
156-PK-DDIs.txt	warfarin	warfarin	19	19	true	negative	Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated.
55-PK-DDIs.txt	magnesium stearate	quinidine	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	magnesium stearate	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	polydextrose	quinidine	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	polydextrose	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine	hypromellose	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine	lactose monohydrate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine	polyethylene glycol	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine	povidone	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine	triacetin	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine sulfate	hypromellose	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine sulfate	lactose monohydrate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine sulfate	polyethylene glycol	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine sulfate	povidone	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine sulfate	quinidine	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	quinidine sulfate	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
55-PK-DDIs.txt	triacetin	quinidine sulfate	1	1	true	positive	Each Quinidine Sulfate Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.
90-PK-DDIs.txt	atomoxetine	acetylsalicylic acid	19	20	true	negative	7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	atomoxetine	atomoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	atomoxetine	desipramine	13	15	true	negative	CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.  No dose adjustment is recommended for drugs metabolized by CYP3A.  CYP2D6 Substrate (e.g., Desipramine) — Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine.
90-PK-DDIs.txt	atomoxetine	fluoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	atomoxetine	p450	4	6	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).  In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.  In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
90-PK-DDIs.txt	atomoxetine hydrochloride	acetylsalicylic acid	18	20	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	atomoxetine hydrochloride	phenytoin	18	20	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	desipramine	atomoxetine	15	13	true	negative	CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.  No dose adjustment is recommended for drugs metabolized by CYP3A.  CYP2D6 Substrate (e.g., Desipramine) — Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine.
90-PK-DDIs.txt	diazepam	acetylsalicylic acid	20	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	diazepam	atomoxetine	20	19	true	negative	7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	diazepam	atomoxetine hydrochloride	20	18	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	diazepam	methylphenidate	20	18	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	diazepam	omeprazole	20	22	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.  Similarly, these compounds did not affect the binding of atomoxetine to human albumin.  7.9 Drugs that Affect Gastric pH    Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.
90-PK-DDIs.txt	diazepam	phenytoin	20	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	diazepam	warfarin	20	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	fluoxetine	atomoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	methylphenidate	acetylsalicylic acid	18	20	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	methylphenidate	warfarin	18	20	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	midazolam	albuterol	13	11	true	negative	However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol (200 to 800 mcg) and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were excluded for poor metabolizer status.  7.5 Effect of Atomoxetine on P450 Enzymes    Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.  CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.
90-PK-DDIs.txt	midazolam	atomoxetine	13	11	true	negative	However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol (200 to 800 mcg) and atomoxetine (80 mg QD for 5 days) in 21 healthy Asian subjects who were excluded for poor metabolizer status.  7.5 Effect of Atomoxetine on P450 Enzymes    Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.  CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.
90-PK-DDIs.txt	midazolam	desipramine	13	15	true	negative	CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.  No dose adjustment is recommended for drugs metabolized by CYP3A.  CYP2D6 Substrate (e.g., Desipramine) — Coadministration of atomoxetine hydrochloride (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine.
90-PK-DDIs.txt	midazolam	p450	13	12	true	negative	7.5 Effect of Atomoxetine on P450 Enzymes    Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.  CYP3A Substrate (e.g., Midazolam) — Coadministration of atomoxetine hydrochloride (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam.
90-PK-DDIs.txt	omeprazole	acetylsalicylic acid	22	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.  Similarly, these compounds did not affect the binding of atomoxetine to human albumin.  7.9 Drugs that Affect Gastric pH    Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.
90-PK-DDIs.txt	omeprazole	atomoxetine	22	21	true	negative	Similarly, these compounds did not affect the binding of atomoxetine to human albumin.  7.9 Drugs that Affect Gastric pH    Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.
90-PK-DDIs.txt	omeprazole	atomoxetine hydrochloride	22	22	true	negative	7.9 Drugs that Affect Gastric pH    Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.
90-PK-DDIs.txt	omeprazole	phenytoin	22	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.  Similarly, these compounds did not affect the binding of atomoxetine to human albumin.  7.9 Drugs that Affect Gastric pH    Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.
90-PK-DDIs.txt	p450	atomoxetine	6	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).  In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.  In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
90-PK-DDIs.txt	p450	fluoxetine	6	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).  In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.  In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
90-PK-DDIs.txt	paroxetine	atomoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	paroxetine	fluoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	paroxetine	p450	4	6	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).  In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.  In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
90-PK-DDIs.txt	paroxetine	quinidine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	phenytoin	acetylsalicylic acid	20	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	phenytoin	atomoxetine	20	19	true	negative	7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	phenytoin	atomoxetine hydrochloride	20	18	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	phenytoin	methylphenidate	20	18	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	quinidine	atomoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	quinidine	fluoxetine	4	4	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).
90-PK-DDIs.txt	quinidine	p450	4	6	true	positive	7.2 Effect of CYP2D6 Inhibitors on Atomoxetine    In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs).  In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.  In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
90-PK-DDIs.txt	warfarin	acetylsalicylic acid	20	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	warfarin	atomoxetine	20	19	true	negative	7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	warfarin	atomoxetine hydrochloride	20	18	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	warfarin	methylphenidate	20	18	true	negative	7.7 Methylphenidate    Coadministration of methylphenidate with atomoxetine hydrochloride did not increase cardiovascular effects beyond those seen with methylphenidate alone.  7.8 Drugs Highly Bound to Plasma Protein    In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations.  Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
90-PK-DDIs.txt	warfarin	omeprazole	20	22	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.  Similarly, these compounds did not affect the binding of atomoxetine to human albumin.  7.9 Drugs that Affect Gastric pH    Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine hydrochloride bioavailability.
90-PK-DDIs.txt	warfarin	phenytoin	20	20	true	negative	Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
170-PK-DDIs.txt	hydrochlorothiazide	cholestyramine	6	6	true	positive	Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
170-PK-DDIs.txt	hydrochlorothiazide	colestipol	6	6	true	positive	Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
170-PK-DDIs.txt	norepinephrine	cholestyramine	9	7	true	positive	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.  Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.  Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
170-PK-DDIs.txt	norepinephrine	colestipol	9	7	true	positive	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.  Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.  Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
170-PK-DDIs.txt	norepinephrine	hydrochlorothiazide	9	7	true	positive	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.  Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.  Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
170-PK-DDIs.txt	thiazide	norepinephrine	7	9	true	positive	Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.  Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.  Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
76-PK-DDIs.txt	citalopram	cimetidine	1	1	true	positive	In subjects who had received 21 days of 40 mg/day citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
188-PK-DDIs.txt	atazanavir	atazanavir sulfate	23	23	true	positive	Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state.
188-PK-DDIs.txt	atazanavir sulfate	reyataz	23	21	true	positive	Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in Cmax relative to the fasting state.  Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in Cmax relative to the fasting state.  Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately one half compared to the fasting state.
188-PK-DDIs.txt	glycoprotein	atazanavir	29	29	true	positive	Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively).
148-PK-DDIs.txt	carbamazepine	carbamazepine	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
148-PK-DDIs.txt	felbamate	carbamazepine	3	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.  In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL.  The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
148-PK-DDIs.txt	felbamate	felbatol	3	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.  In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8±2 micrograms/mL.  The carbamazepine steady-state Cmin decreased 31% to 5±1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
148-PK-DDIs.txt	felbatol	carbamazepine	1	1	true	positive	Carbamazepine: Felbatol® causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
194-PK-DDIs.txt	amiodarone	amiodarone	4	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.
194-PK-DDIs.txt	amiodarone	fluoxetine	4	6	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.
194-PK-DDIs.txt	cimetidine	amiodarone	5	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.
194-PK-DDIs.txt	cimetidine	cimetidine	5	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.
194-PK-DDIs.txt	cimetidine	propafenone	5	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.
194-PK-DDIs.txt	digoxin	digoxin	17	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.
194-PK-DDIs.txt	digoxin	warfarin	17	19	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
194-PK-DDIs.txt	fluoxetine	amiodarone	6	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.
194-PK-DDIs.txt	fluoxetine	cimetidine	6	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.
194-PK-DDIs.txt	fluoxetine	fluoxetine	6	6	true	positive	Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.
194-PK-DDIs.txt	fluoxetine	propafenone	6	4	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.
194-PK-DDIs.txt	orlistat	metoprolol	22	24	true	positive	In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.  7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.  In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.
194-PK-DDIs.txt	orlistat	propafenone	21	19	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.  Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).  7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.
194-PK-DDIs.txt	orlistat	warfarin	21	19	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.  Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).  7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.
194-PK-DDIs.txt	propafenone	cimetidine	4	5	true	positive	Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.
194-PK-DDIs.txt	propafenone	metoprolol	23	25	true	positive	7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.  In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.  The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.
194-PK-DDIs.txt	propranolol	metoprolol	23	25	true	positive	7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.  In 4 patients, administration of metoprolol with propafenone increased the metoprolol plasma concentrations at steady state by 100-400%.  The pharmacokinetics of propafenone was not affected by the coadministration of either propranolol or metoprolol.
194-PK-DDIs.txt	propranolol	orlistat	23	21	true	positive	7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.  In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.  7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.
194-PK-DDIs.txt	propranolol	propafenone	23	21	true	positive	7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.  In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure.  7.5 Beta-Antagonists    Concomitant use of propafenone and propranolol in healthy subjects increased propranolol plasma concentrations at steady state by 113%.
194-PK-DDIs.txt	prothrombin	digoxin	19	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
194-PK-DDIs.txt	prothrombin	orlistat	19	21	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.  Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).  7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.
194-PK-DDIs.txt	prothrombin	propafenone	19	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
194-PK-DDIs.txt	quinidine	cimetidine	7	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.  Quinidine    Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)].
194-PK-DDIs.txt	quinidine	fluoxetine	7	6	true	positive	Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.  Quinidine    Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)].
194-PK-DDIs.txt	quinidine	propafenone	7	5	true	positive	Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  Fluoxetine    Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50%.  Quinidine    Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12)].
194-PK-DDIs.txt	rythmol	cimetidine	3	5	true	positive	Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided [see Warnings and Precautions (5.2) and Dosage and Administration (2)].  Amiodarone    Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.  Cimetidine    Concomitant administration of propafenone immediate release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.
194-PK-DDIs.txt	warfarin	digoxin	19	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
194-PK-DDIs.txt	warfarin	orlistat	19	21	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.  Adjust the warfarin dose as needed by monitoring INR (international normalized ratio).  7.4 Orlistat    Orlistat may limit the fraction of propafenone available for absorption.
194-PK-DDIs.txt	warfarin	propafenone	19	17	true	positive	7.2 Digoxin    Concomitant use of propafenone and digoxin increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270%, and decreased the clearance of digoxin by 31 to 67%.  Monitor plasma digoxin levels of patients receiving propafenone and adjust digoxin dosage as needed.  7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
194-PK-DDIs.txt	warfarin	prothrombin	19	19	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
194-PK-DDIs.txt	warfarin	warfarin	19	19	true	positive	7.3 Warfarin    The concomitant administration of propafenone and warfarin increased warfarin plasma concentrations at steady state by 39% in healthy volunteers and prolonged the prothrombin time (PT) in patients taking warfarin.
31-PK-DDIs.txt	fluconazole	glyburide	1	1	true	positive	The AUC and Cmax of glyburide (5 mg single dose) were significantly increased following the administration of fluconazole in 20 normal male volunteers.
175-PK-DDIs.txt	nelfinavir	tacrolimus	2	2	true	positive	However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus.
175-PK-DDIs.txt	phenytoin	tacrolimus	5	3	true	positive	Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.  Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly.  Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration.
175-PK-DDIs.txt	ritonavir	tacrolimus	2	2	true	positive	However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus.
175-PK-DDIs.txt	tacrolimus	ganciclovir	2	2	true	positive	However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus.
147-PK-DDIs.txt	felbamate	felbatol	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.
147-PK-DDIs.txt	felbamate	phenytoin	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.
147-PK-DDIs.txt	phenytoin	felbatol	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.
147-PK-DDIs.txt	phenytoin	phenytoin	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.
140-PK-DDIs.txt	fexofenadine	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.
140-PK-DDIs.txt	fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.
140-PK-DDIs.txt	fexofenadine hydrochloride	fexofenadine hydrochloride	35	35	true	negative	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.
140-PK-DDIs.txt	glycoprotein	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
8-PK-DDIs.txt	debrisoquin	9-hydroxyrisperidone	30	32	true	positive	CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs.  CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably quinidine.  Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly.
8-PK-DDIs.txt	debrisoquin	quinidine	30	31	true	positive	CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs.  CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably quinidine.
8-PK-DDIs.txt	risperidone	haloperidol	3	5	true	positive	Risperidone is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors.  Risperidone acts as an antagonist at other receptors, but with lower potency.  Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations >10-5 M) for cholinergic muscarinic or β1 and β2 adrenergic receptors.
132-PK-DDIs.txt	fluvastatin	pravastatin	2	1	true	negative	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.  Propranolol did not have an effect on the pharmacokinetics of fluvastatin.
132-PK-DDIs.txt	fluvastatin	propranolol	2	1	true	negative	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.  Propranolol did not have an effect on the pharmacokinetics of fluvastatin.
132-PK-DDIs.txt	lovastatin	fluvastatin	1	2	true	negative	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.  Propranolol did not have an effect on the pharmacokinetics of fluvastatin.
132-PK-DDIs.txt	lovastatin	pravastatin	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.
132-PK-DDIs.txt	lovastatin	propranolol	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.
132-PK-DDIs.txt	pravastatin	propranolol	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.
132-PK-DDIs.txt	propranolol	propranolol	1	1	true	positive	Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.
109-PK-DDIs.txt	diltiazem	diltiazem	1	1	true	positive	Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.
109-PK-DDIs.txt	nifedipine	diltiazem	1	1	true	positive	Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.
103-PK-DDIs.txt	aldosterone	apomorphine	11	9	true	positive	Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.  Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see Warnings and Precautions (5.2), (5.3)].  Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
103-PK-DDIs.txt	aldosterone	dopamine	11	10	true	positive	Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see Warnings and Precautions (5.2), (5.3)].  Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
103-PK-DDIs.txt	aldosterone	metoclopramide	11	9	true	positive	Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.  Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see Warnings and Precautions (5.2), (5.3)].  Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
103-PK-DDIs.txt	aldosterone	prolactin	11	11	true	positive	Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
103-PK-DDIs.txt	dopamine	prolactin	10	11	true	positive	Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see Warnings and Precautions (5.2), (5.3)].  Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
103-PK-DDIs.txt	metoclopramide	metozolv	25	23	true	positive	In a food-effect study with 28 subjects, METOZOLV ODT taken immediately after a high-fat meal had a 17% lower peak blood level than when taken after an overnight fast.  The time to peak blood levels increased from about 1.75 hours under fasted conditions to 3 hours when taken immediately after a high-fat meal.  The extent of metoclopramide absorbed (area under the curve) was comparable whether METOZOLV ODT was administered with or without food.
103-PK-DDIs.txt	metoclopramide	prolactin	9	11	true	positive	Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.  Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see Warnings and Precautions (5.2), (5.3)].  Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
103-PK-DDIs.txt	prolactin	apomorphine	11	9	true	positive	Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.  Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see Warnings and Precautions (5.2), (5.3)].  Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.
171-PK-DDIs.txt	glucuronide	p450	36	37	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.
171-PK-DDIs.txt	hydrochlorothiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.
171-PK-DDIs.txt	thiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.
59-PK-DDIs.txt	carbamazepine	nefazodone	1	1	true	positive	Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect.
29-PK-DDIs.txt	fluconazole	tolbutamide	1	1	true	positive	In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.
29-PK-DDIs.txt	tolbutamide	tolbutamide	1	1	true	positive	In 13 normal male volunteers, there was significant increase in tolbutamide (500 mg single dose) AUC and Cmax following the administration of fluconazole.
195-PK-DDIs.txt	isoproterenol	propafenone	7	5	true	positive	Propafenone reduces spontaneous automaticity and depresses triggered activity.  Studies in anesthetized dogs and isolated organ preparations show that propafenone has beta-sympatholytic activity at about 1/50 the potency of propranolol.  Clinical studies employing isoproterenol challenge and exercise testing after single doses of propafenone indicate a beta-adrenergic blocking potency (per mg) about 1/40 that of propranolol in man.
195-PK-DDIs.txt	propafenone	procaine	9	11	true	positive	At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium, but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.  Moreover, propafenone inhibits a variety of cardiac potassium currents in in vitro studies (i.e. the transient outward, the delayed rectifier, and the inward rectifier current).  Propafenone has local anesthetic activity approximately equal to procaine.
195-PK-DDIs.txt	propafenone	propranolol	5	6	true	positive	Propafenone reduces spontaneous automaticity and depresses triggered activity.  Studies in anesthetized dogs and isolated organ preparations show that propafenone has beta-sympatholytic activity at about 1/50 the potency of propranolol.
24-PK-DDIs.txt	fluconazole	fluconazole	1	1	true	positive	Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.
24-PK-DDIs.txt	rifampin	fluconazole	1	1	true	positive	Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole.
11-PK-DDIs.txt	sertraline	cimetidine	1	1	true	positive	In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group.
161-PK-DDIs.txt	azithromycin	nelfinavir	1	1	true	positive	Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations.
18-PK-DDIs.txt	sertraline	atenolol	1	1	true	negative	Sertraline (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.
201-PK-DDIs.txt	phenytoin	methadone	1	1	true	positive	Phenytoin    In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently.
201-PK-DDIs.txt	phenytoin	phenytoin	1	1	true	positive	Phenytoin    In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently.
182-PK-DDIs.txt	basis	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.
182-PK-DDIs.txt	norverapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.
182-PK-DDIs.txt	norverapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.
182-PK-DDIs.txt	procaine	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.
182-PK-DDIs.txt	verapamil hydrochloride	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.
182-PK-DDIs.txt	verapamil hydrochloride	verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.
157-PK-DDIs.txt	angiotensinogen	aliskiren	9	9	true	positive	Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known.
145-PK-DDIs.txt	felbamate	valproate	2	1	true	negative	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.  Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol® (felbamate) plasma concentrations.
145-PK-DDIs.txt	felbatol	valproate	1	1	true	negative	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.
145-PK-DDIs.txt	valproate	valproate	1	1	true	negative	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol® at steady-state.
74-PK-DDIs.txt	ampicillin	p450	1	3	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	benzodiazepines	voriconazole	7	9	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	cyclosporine	voriconazole	7	9	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	diazepam	ampicillin	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	diazepam	ketoconazole	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	diazepam	omeprazole	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	diazepam	p450	3	3	true	positive	Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	diazepam	phenytoin	3	3	true	positive	Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	diazepam	warfarin	3	3	true	positive	Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	disulfiram	voriconazole	7	9	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	ketoconazole	p450	1	3	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	ketoconazole	phenytoin	1	3	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	ketoconazole	warfarin	1	3	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	omeprazole	atazanavir	12	13	true	positive	When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.  Antiretroviral Agents    Concomitant use of atazanavir and proton pump inhibitors is not recommended.
74-PK-DDIs.txt	omeprazole	benzodiazepines	8	7	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.
74-PK-DDIs.txt	omeprazole	cyclosporine	8	7	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.
74-PK-DDIs.txt	omeprazole	disulfiram	8	7	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.
74-PK-DDIs.txt	omeprazole	p450	1	3	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	omeprazole	prothrombin	2	4	true	positive	In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.  There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly.
74-PK-DDIs.txt	omeprazole	saquinavir	21	23	true	positive	Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.  Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.  For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.
74-PK-DDIs.txt	omeprazole	theophylline	8	7	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.
74-PK-DDIs.txt	omeprazole	voriconazole	8	9	true	positive	Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	phenytoin	ampicillin	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	phenytoin	omeprazole	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	phenytoin	p450	3	3	true	positive	Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	phenytoin	warfarin	3	3	true	positive	Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	propranolol	omeprazole	7	8	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.
74-PK-DDIs.txt	propranolol	voriconazole	7	9	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	prothrombin	omeprazole	4	2	true	positive	In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.  There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly.
74-PK-DDIs.txt	ritonavir	atazanavir	23	21	true	positive	Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.  Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.  For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.
74-PK-DDIs.txt	ritonavir	omeprazole	23	21	true	positive	Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.  Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.  For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.
74-PK-DDIs.txt	ritonavir	saquinavir	23	23	true	positive	For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.
74-PK-DDIs.txt	saquinavir	atazanavir	23	21	true	positive	Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.  Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.  For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.
74-PK-DDIs.txt	saquinavir	omeprazole	23	21	true	positive	Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.  Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.  For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.
74-PK-DDIs.txt	tacrolimus	tacrolimus	26	26	true	positive	Tacrolimus    Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus.
74-PK-DDIs.txt	theophylline	voriconazole	7	9	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	voriconazole	atazanavir	12	13	true	positive	When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.  Antiretroviral Agents    Concomitant use of atazanavir and proton pump inhibitors is not recommended.
74-PK-DDIs.txt	voriconazole	p450	9	7	true	positive	Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines).  Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.  Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.
74-PK-DDIs.txt	warfarin	ampicillin	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	warfarin	omeprazole	3	1	true	positive	7 DRUG INTERACTIONS    Drugs for which gastric pH can affect bioavailability    Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts).  In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.  Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
74-PK-DDIs.txt	warfarin	p450	3	3	true	positive	Drugs metabolized by cytochrome P450 (CYP)    Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver.
99-PK-DDIs.txt	alprazolam	propoxyphene	1	1	true	positive	Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
57-PK-DDIs.txt	zonisamide	cimetidine	1	1	true	negative	Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).
123-PK-DDIs.txt	acarbose	glimepiride	73	71	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.
123-PK-DDIs.txt	acarbose	rosiglitazone	73	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.
123-PK-DDIs.txt	alcohol	avandia	76	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.
123-PK-DDIs.txt	alcohol	ethanol	76	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.
123-PK-DDIs.txt	avandia	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.
123-PK-DDIs.txt	avandia	insulin	13	11	true	negative	The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue.  Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.
123-PK-DDIs.txt	digoxin	acarbose	74	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.
123-PK-DDIs.txt	digoxin	alcohol	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.
123-PK-DDIs.txt	digoxin	avandia	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.
123-PK-DDIs.txt	digoxin	digoxin	74	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.
123-PK-DDIs.txt	digoxin	ethanol	74	76	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.
123-PK-DDIs.txt	digoxin	rosiglitazone	74	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.
123-PK-DDIs.txt	ethanol	avandia	76	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.
123-PK-DDIs.txt	ethanol	rosiglitazone	76	77	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	ethinyl estradiol	avandia	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.
123-PK-DDIs.txt	ethinyl estradiol	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	ethinyl estradiol	norethindrone	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.
123-PK-DDIs.txt	ethinyl estradiol	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	gemfibrozil	avandia	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	gemfibrozil	gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	glimepiride	acarbose	71	73	true	negative	No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.
123-PK-DDIs.txt	glimepiride	metformin	70	72	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.
123-PK-DDIs.txt	glyburide	avandia	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.
123-PK-DDIs.txt	glyburide	glyburide	68	68	true	positive	Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.
123-PK-DDIs.txt	metformin	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.
123-PK-DDIs.txt	metformin	avandia	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.
123-PK-DDIs.txt	metformin	digoxin	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.
123-PK-DDIs.txt	metformin	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.
123-PK-DDIs.txt	metformin	metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.
123-PK-DDIs.txt	nifedipine	avandia	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.
123-PK-DDIs.txt	nifedipine	ethinyl estradiol	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.
123-PK-DDIs.txt	nifedipine	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	nifedipine	norethindrone	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.
123-PK-DDIs.txt	nifedipine	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	norethindrone	avandia	64	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.
123-PK-DDIs.txt	norethindrone	gemfibrozil	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	norethindrone	rosiglitazone	64	65	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	ranitidine	alcohol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	ranitidine	avandia	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	ranitidine	ethanol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	ranitidine	ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	ranitidine	warfarin	77	75	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	rifampin	avandia	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.
123-PK-DDIs.txt	rifampin	glyburide	67	68	true	positive	Rifampin    Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4    Glyburide    AVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.  Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.
123-PK-DDIs.txt	rosiglitazone	acarbose	72	73	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.
123-PK-DDIs.txt	rosiglitazone	alcohol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	rosiglitazone	avandia	65	64	true	negative	AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.  Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	rosiglitazone	cholesterol	12	14	true	negative	Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.  12.2 Pharmacodynamics    Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA.  In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids.
123-PK-DDIs.txt	rosiglitazone	digoxin	72	74	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.  Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.
123-PK-DDIs.txt	rosiglitazone	ethanol	77	76	true	negative	Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	rosiglitazone	gemfibrozil	65	65	true	positive	Gemfibrozil    Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.
123-PK-DDIs.txt	rosiglitazone	glimepiride	72	70	true	negative	Glimepiride    Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.  No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.  Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.
123-PK-DDIs.txt	rosiglitazone	metformin	72	72	true	negative	Metformin    Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.
123-PK-DDIs.txt	rosiglitazone	ranitidine	77	77	true	negative	Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	warfarin	acarbose	75	73	true	negative	Acarbose    Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.  Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.
123-PK-DDIs.txt	warfarin	digoxin	75	74	true	negative	Digoxin    Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.  Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.
123-PK-DDIs.txt	warfarin	ranitidine	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
123-PK-DDIs.txt	warfarin	rosiglitazone	75	77	true	negative	Warfarin    Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.  Ethanol    A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.  Ranitidine    Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.
42-PK-DDIs.txt	azathioprine	allopurinol sodium	1	1	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
42-PK-DDIs.txt	azathioprine	basis	1	2	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.  Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).
42-PK-DDIs.txt	mercaptopurine	allopurinol sodium	1	1	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
42-PK-DDIs.txt	mercaptopurine	azathioprine	1	1	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
42-PK-DDIs.txt	mercaptopurine	basis	1	2	true	positive	In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.  Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).
168-PK-DDIs.txt	clonazepam	carbamazepine	1	1	true	negative	Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.
168-PK-DDIs.txt	clonazepam	phenobarbital	1	1	true	negative	Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.
168-PK-DDIs.txt	phenytoin	clonazepam	1	1	true	negative	Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.
105-PK-DDIs.txt	conivaptan	conivaptan	34	34	true	positive	However, following administration of oral conivaptan in patients with renal impairment (CLcr 30 - 60 mL/min or CLcr 10 - 29 mL/min), the AUCs for conivaptan were 70% and 85% higher, respectively, compared to patients with normal renal function.
105-PK-DDIs.txt	conivaptan	p450	23	24	true	positive	Distribution    Conivaptan is extensively bound to human plasma proteins, being 99% bound over the concentration range of approximately 10 to 1000 ng/mL.  Metabolism and Excretion    CYP3A was identified as the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan.
105-PK-DDIs.txt	conivaptan hydrochloride	conivaptan	16	14	true	negative	The pharmacokinetics of conivaptan following intravenous infusion (40 mg/day to 80 mg/day) and oral administration are non-linear, and inhibition by conivaptan of its own metabolism seems to be the major factor for the non-linearity.  The intersubject variability of conivaptan pharmacokinetics is high (94% CV in CL).  The pharmacokinetics of conivaptan and its metabolites were characterized in healthy male subjects administered conivaptan hydrochloride as a 20 mg loading dose (infused over 30 minutes) followed by a continuous infusion of 40 mg/day for 3 days.
23-PK-DDIs.txt	fluconazole	cimetidine	1	1	true	negative	Fluconazole 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers.
92-PK-DDIs.txt	sirolimus	sirolimus	1	1	true	positive	Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects.
92-PK-DDIs.txt	sirolimus	voriconazole	1	1	true	positive	Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects.
151-PK-DDIs.txt	felbamate	felbatol	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.
151-PK-DDIs.txt	felbamate	phenytoin	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.
151-PK-DDIs.txt	phenytoin	felbatol	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.
151-PK-DDIs.txt	phenytoin	phenytoin	1	1	true	positive	Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol® (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.
136-PK-DDIs.txt	indinavir	trazodone	1	1	true	positive	In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.
136-PK-DDIs.txt	ketoconazole	trazodone	1	1	true	positive	In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.
136-PK-DDIs.txt	ritonavir	trazodone	1	1	true	positive	In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.
84-PK-DDIs.txt	cimetidine	tacrine	1	1	true	positive	Cimetidine increased the Cmax and AUC of tacrine by approximately 54% and 64%, respectively.
9-PK-DDIs.txt	alcohol	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.
9-PK-DDIs.txt	alcohol	clozapine	20	22	true	positive	As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	alcohol	ethanol	19	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	alcohol	lorazepam	19	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	alosetron	diltiazem	42	44	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	amitriptyline	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	amitriptyline	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	amitriptyline	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	benzodiazepines	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	benzodiazepines	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	benzodiazepines	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	benzodiazepines	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	carbamazepine	carbamazepine	21	21	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.
9-PK-DDIs.txt	carbamazepine	clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	carbamazepine	ethanol	21	19	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.
9-PK-DDIs.txt	clomipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	clomipramine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	clomipramine	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	clomipramine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	diazepam	fluvoxamine	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	diazepam	fluvoxamine maleate	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	diazepam	lorazepam	16	17	true	negative	Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	digoxin	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
9-PK-DDIs.txt	digoxin	fluvoxamine	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
9-PK-DDIs.txt	digoxin	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
9-PK-DDIs.txt	diltiazem	alosetron	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	diltiazem	digoxin	44	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	diltiazem	diltiazem	44	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	diltiazem	lotronex	44	42	true	negative	7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	fluvoxamine	alcohol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	fluvoxamine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine	aspirin	55	54	true	positive	Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].  7.4 Effects of Smoking on Fluvoxamine Metabolism    Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.
9-PK-DDIs.txt	fluvoxamine	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.
9-PK-DDIs.txt	fluvoxamine	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.
9-PK-DDIs.txt	fluvoxamine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine	clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	fluvoxamine	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
9-PK-DDIs.txt	fluvoxamine	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	fluvoxamine	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	fluvoxamine	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	fluvoxamine	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.
9-PK-DDIs.txt	fluvoxamine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	fluvoxamine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	fluvoxamine maleate	alcohol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	fluvoxamine maleate	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	fluvoxamine maleate	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine maleate	atenolol	51	51	true	negative	Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.
9-PK-DDIs.txt	fluvoxamine maleate	carbamazepine	19	21	true	negative	Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.  As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.  Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.
9-PK-DDIs.txt	fluvoxamine maleate	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine maleate	clozapine	21	22	true	positive	Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.  Clozapine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	fluvoxamine maleate	digoxin	43	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
9-PK-DDIs.txt	fluvoxamine maleate	diltiazem	43	44	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
9-PK-DDIs.txt	fluvoxamine maleate	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	fluvoxamine maleate	fluvoxamine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine maleate	imipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine maleate	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	fluvoxamine maleate	methadone	24	25	true	positive	Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.  Methadone: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	fluvoxamine maleate	metoprolol	46	48	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.  In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.  One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.
9-PK-DDIs.txt	fluvoxamine maleate	mexiletine	43	45	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	fluvoxamine maleate	propranolol	46	46	true	positive	Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.
9-PK-DDIs.txt	fluvoxamine maleate	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	fluvoxamine maleate	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine maleate	tizanidine	34	33	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	fluvoxamine maleate	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	fluvoxamine maleate	tryptophan	43	41	true	negative	Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).  7.3 Other Drugs    Alosetron: See CONTRAINDICATIONS [4], WARNINGS AND PRECAUTIONS [5.7], and Lotronex® (alosetron) package insert.  Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
9-PK-DDIs.txt	imipramine	amitriptyline	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	imipramine	clomipramine	34	34	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	imipramine	serotonin	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	imipramine	thioridazine	34	32	true	positive	Thioridazine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).  Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	imipramine	triptan	34	36	true	positive	Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.  Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.  Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
9-PK-DDIs.txt	lorazepam	alprazolam	17	15	true	negative	Alprazolam: See WARNINGS AND PRECAUTIONS (5.8).  Diazepam: See WARNINGS AND PRECAUTIONS (5.8).  Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	lorazepam	ethanol	17	19	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.  On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.  Alcohol: Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
9-PK-DDIs.txt	lorazepam	lorazepam	17	17	true	negative	Lorazepam: A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
9-PK-DDIs.txt	mexiletine	digoxin	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	mexiletine	fluvoxamine	45	43	true	negative	Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.  Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).
9-PK-DDIs.txt	phenytoin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	phenytoin	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	phenytoin	theophylline	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	pimozide	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	pimozide	omeprazole	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	pimozide	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	pimozide	warfarin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	propranolol	diltiazem	46	44	true	positive	Diltiazem: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.  Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.
9-PK-DDIs.txt	propranolol	mexiletine	46	45	true	positive	Mexiletine: See WARNINGS AND PRECAUTIONS (5.8).  Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.
9-PK-DDIs.txt	sumatriptan	sumatriptan	38	38	true	negative	Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
9-PK-DDIs.txt	theophylline	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	theophylline	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	theophylline	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	tizanidine	amitriptyline	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	tizanidine	clomipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	tizanidine	fluvoxamine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	tizanidine	imipramine	33	34	true	positive	Tizanidine: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).  Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
9-PK-DDIs.txt	warfarin	benzodiazepines	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	warfarin	phenytoin	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
9-PK-DDIs.txt	warfarin	pimozide	11	11	true	positive	A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
19-PK-DDIs.txt	sertraline	digoxin	1	1	true	negative	In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.
120-PK-DDIs.txt	coumarin	metronidazole	1	1	true	positive	Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.
120-PK-DDIs.txt	prothrombin	metronidazole	1	1	true	positive	Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.
120-PK-DDIs.txt	warfarin	metronidazole	1	1	true	positive	Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time.
129-PK-DDIs.txt	aluminum hydroxide gel	cimetidine	2	1	true	positive	Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.  Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.
129-PK-DDIs.txt	aluminum hydroxide gel	propranolol	2	1	true	positive	Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.  Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.
129-PK-DDIs.txt	propranolol	cimetidine	1	1	true	positive	Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.
202-PK-DDIs.txt	voriconazole	methadone	1	1	true	positive	Voriconazole    Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD).
202-PK-DDIs.txt	voriconazole	voriconazole	1	1	true	positive	Voriconazole    Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD).
183-PK-DDIs.txt	prothrombin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.
183-PK-DDIs.txt	tacrolimus	prothrombin	9	7	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.
183-PK-DDIs.txt	theophylline	amoxicillin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.
183-PK-DDIs.txt	theophylline	clarithromycin	10	12	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.  Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.  [See Clinical Pharmacology (12.5)]    For information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.
183-PK-DDIs.txt	theophylline	prothrombin	10	8	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.
183-PK-DDIs.txt	theophylline	tacrolimus	10	9	true	positive	[See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.
183-PK-DDIs.txt	theophylline	theophylline	10	10	true	positive	Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.
183-PK-DDIs.txt	warfarin	prothrombin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).
183-PK-DDIs.txt	warfarin	tacrolimus	8	9	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.
183-PK-DDIs.txt	warfarin	theophylline	8	10	true	positive	Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  [See Clinical Pharmacology (12.5)]    Tacrolimus    Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.  Theophylline    A minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.
183-PK-DDIs.txt	warfarin	warfarin	5	5	true	negative	[See Clinical Pharmacology (12.5)]    Warfarin    In a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).
5-PK-DDIs.txt	alprazolam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	alprazolam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	alprazolam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	alprazolam	venlafaxine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	caffeine	venlafaxine	51	51	true	negative	This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate.
5-PK-DDIs.txt	cimetidine	cimetidine	3	3	true	positive	7.2 Cimetidine    Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.
5-PK-DDIs.txt	desipramine	metoprolol	35	36	true	negative	The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.
5-PK-DDIs.txt	diazepam	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	diazepam	alprazolam	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	diazepam	diazepam	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).
5-PK-DDIs.txt	diazepam	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	diazepam	risperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	diazepam	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	diazepam	venlafaxine	54	54	true	negative	CYP2C19    Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above).
5-PK-DDIs.txt	haloperidol	haloperidol	11	11	true	positive	7.4 Haloperidol    Venlafaxine administered under steady-state conditions at 150 mg/day in 24 healthy subjects decreased total oral-dose clearance (Cl/F) of a single 2 mg dose of haloperidol by 42%, which resulted in a 70% increase in haloperidol AUC.
5-PK-DDIs.txt	imipramine	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.
5-PK-DDIs.txt	imipramine	imipramine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	imipramine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.
5-PK-DDIs.txt	imipramine	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	indinavir	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	indinavir	venlafaxine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	ketoconazole	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.
5-PK-DDIs.txt	odv	alprazolam	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	odv	desipramine	34	35	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.
5-PK-DDIs.txt	odv	imipramine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	odv	indinavir	48	48	true	negative	Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	odv	ketoconazole	22	22	true	positive	Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n=14) and 25 mg in poor metabolizers (PM;n=6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O-desmethylvenlafaxine (ODV) in most subjects following administration of ketoconazole.
5-PK-DDIs.txt	odv	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.
5-PK-DDIs.txt	odv	terfenadine	48	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	odv	venlafaxine	34	34	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	risperidone	9-hydroxyrisperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
5-PK-DDIs.txt	risperidone	alprazolam	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	risperidone	risperidone	43	43	true	positive	Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
5-PK-DDIs.txt	risperidone	terfenadine	44	46	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	risperidone	venlafaxine hydrochloride	43	42	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
5-PK-DDIs.txt	terfenadine	9-hydroxyrisperidone	46	44	true	negative	However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone).  CYP3A4    Venlafaxine did not inhibit CYP3A4 in vitro.  This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	terfenadine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	venlafaxine	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
5-PK-DDIs.txt	venlafaxine	desipramine	31	32	true	negative	Imipramine - Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine.  However, desipramine AUC, Cmax, and Cmin increased by about 35% in the presence of venlafaxine.
5-PK-DDIs.txt	venlafaxine	indinavir	46	48	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.  Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax.  Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.
5-PK-DDIs.txt	venlafaxine	metoprolol	34	36	true	negative	Imipramine did not affect the pharmacokinetics of venlafaxine and ODV.  The clinical significance of elevated 2-OH-desipramine levels is unknown.  Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30 to 40% without altering the plasma concentrations of its active metabolite, α-hydroxymetoprolol.
5-PK-DDIs.txt	venlafaxine	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
5-PK-DDIs.txt	venlafaxine	terfenadine	46	46	true	negative	This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
5-PK-DDIs.txt	venlafaxine hydrochloride	9-hydroxyrisperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
5-PK-DDIs.txt	venlafaxine hydrochloride	metoprolol	42	40	true	positive	Caution should be exercised with co-administration of venlafaxine and metoprolol.  Venlafaxine treatment has been associated with dose-related increases in blood pressure in some patients.  It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].
5-PK-DDIs.txt	venlafaxine hydrochloride	risperidone	42	43	true	positive	It is recommended that patients receiving Venlafaxine hydrochloride extended-release tablets have regular monitoring of blood pressure [see Warnings and Precautions (5.5)].  Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC.
95-PK-DDIs.txt	alprazolam	nefazodone	1	1	true	positive	Coadministration of nefazodone increased alprazolam concentration two-fold.
104-PK-DDIs.txt	captopril	vaprisol	12	10	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.  7.4 Captopril and Furosemide    The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.
104-PK-DDIs.txt	conivaptan	prothrombin	9	11	true	positive	7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.
104-PK-DDIs.txt	conivaptan hydrochloride	digoxin	8	9	true	positive	Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].
104-PK-DDIs.txt	conivaptan hydrochloride	prothrombin	9	11	true	positive	7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.
104-PK-DDIs.txt	conivaptan hydrochloride	vaprisol	8	6	true	positive	VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.  VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.  Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].
104-PK-DDIs.txt	conivaptan hydrochloride	warfarin	8	10	true	positive	Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.
104-PK-DDIs.txt	digoxin	amlodipine	9	8	true	positive	Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].
104-PK-DDIs.txt	digoxin	conivaptan	9	8	true	positive	Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].
104-PK-DDIs.txt	digoxin	digoxin	9	9	true	positive	7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].
104-PK-DDIs.txt	digoxin	prothrombin	9	11	true	positive	7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.
104-PK-DDIs.txt	digoxin	simvastatin	9	7	true	positive	VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.  Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].
104-PK-DDIs.txt	digoxin	vaprisol	9	7	true	positive	VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.  Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].
104-PK-DDIs.txt	furosemide	warfarin	12	10	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.  7.4 Captopril and Furosemide    The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.
104-PK-DDIs.txt	vaprisol	captopril	10	12	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.  7.4 Captopril and Furosemide    The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.
104-PK-DDIs.txt	vaprisol	furosemide	10	12	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.  7.4 Captopril and Furosemide    The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.
104-PK-DDIs.txt	vaprisol	prothrombin	10	11	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.
104-PK-DDIs.txt	warfarin	amlodipine	10	8	true	positive	Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.
104-PK-DDIs.txt	warfarin	captopril	10	12	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.  7.4 Captopril and Furosemide    The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.
104-PK-DDIs.txt	warfarin	conivaptan	10	8	true	positive	Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].  7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.
104-PK-DDIs.txt	warfarin	digoxin	10	9	true	positive	7.2 Digoxin    Coadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].  7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.
104-PK-DDIs.txt	warfarin	furosemide	10	12	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.  7.4 Captopril and Furosemide    The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.
104-PK-DDIs.txt	warfarin	prothrombin	10	11	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.  The corresponding prothrombin time and international normalized ratio values were unchanged.
104-PK-DDIs.txt	warfarin	vaprisol	10	10	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.
104-PK-DDIs.txt	warfarin	warfarin	10	10	true	positive	7.3 Warfarin    VAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.
164-PK-DDIs.txt	meperidine	cimetidine	1	1	true	positive	Cimetidine    Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.
164-PK-DDIs.txt	meperidine	normeperidine	1	1	true	positive	Cimetidine    Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.
164-PK-DDIs.txt	normeperidine	cimetidine	1	1	true	positive	Cimetidine    Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.
118-PK-DDIs.txt	midazolam	synercid	1	1	true	positive	Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.
118-PK-DDIs.txt	nifedipine	midazolam	1	1	true	positive	Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.
118-PK-DDIs.txt	nifedipine	synercid	1	1	true	positive	Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.
79-PK-DDIs.txt	citalopram	prothrombin	1	2	true	negative	Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.  Prothrombin time was increased by 5%, the clinical significance of which is unknown.
79-PK-DDIs.txt	citalopram	warfarin	1	1	true	negative	Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
79-PK-DDIs.txt	warfarin	prothrombin	1	2	true	negative	Administration of 40 mg/day citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.  Prothrombin time was increased by 5%, the clinical significance of which is unknown.
152-PK-DDIs.txt	carbamazepine	carbamazepine	1	1	true	positive	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.
152-PK-DDIs.txt	felbatol	carbamazepine	1	1	true	positive	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol® at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol® as compared to the same dose of Felbatol® given as monotherapy.
56-PK-DDIs.txt	carbamazepine	zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.
56-PK-DDIs.txt	phenytoin	zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.
56-PK-DDIs.txt	zonisamide	valproate	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.
128-PK-DDIs.txt	diazepam	diazepam	1	1	true	positive	Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.
128-PK-DDIs.txt	diazepam	propranolol	1	1	true	positive	Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.
128-PK-DDIs.txt	propranolol	propranolol	1	1	true	positive	Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.
81-PK-DDIs.txt	citalopram	metoprolol	1	1	true	positive	Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol.
181-PK-DDIs.txt	adriamycin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	cimetidine	theophylline	60	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.
181-PK-DDIs.txt	cisplatin	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	cyclophosphamide	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	digitoxin	digitalis	24	22	true	positive	Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.  In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.
181-PK-DDIs.txt	digitoxin	digoxin	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.
181-PK-DDIs.txt	digitoxin	verapamil	24	23	true	positive	In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified.  Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.
181-PK-DDIs.txt	grapefruit	norverapamil	9	10	true	negative	Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.
181-PK-DDIs.txt	paclitaxel	doxorubicin	33	31	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	paclitaxel	oncovin	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	paclitaxel	prednisone	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	paclitaxel	procarbazine	33	32	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	prazosin	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.
181-PK-DDIs.txt	prazosin	verapamil	43	42	true	positive	Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients.  Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.
181-PK-DDIs.txt	quinidine	paclitaxel	34	33	true	positive	Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.  7.9 Quinidine    In a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension.
181-PK-DDIs.txt	rifampin	cimetidine	58	60	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.
181-PK-DDIs.txt	theophylline	cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.
181-PK-DDIs.txt	theophylline	phenobarbital	59	57	true	positive	7.19 Phenobarbital    Phenobarbital therapy may increase verapamil clearance.  7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.
181-PK-DDIs.txt	theophylline	rifampin	59	58	true	positive	7.20 Rifampin    Therapy with rifampin may markedly reduce oral verapamil bioavailability.  7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.
181-PK-DDIs.txt	theophylline	theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.
181-PK-DDIs.txt	verapamil	cimetidine	59	60	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.  7.22 Cimetidine    The interaction between cimetidine and chronically administered verapamil has not been studied.
181-PK-DDIs.txt	verapamil	flecainide	43	45	true	positive	Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.  7.12 Disopyramide    Until data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration.  7.13 Flecainide    A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization.
181-PK-DDIs.txt	verapamil	norverapamil	8	10	true	negative	Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively.  Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control.  Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil.
181-PK-DDIs.txt	verapamil	paclitaxel	31	33	true	positive	7.8 Antineoplastic Agents    Verapamil can increase doxorubicin levels.  The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
181-PK-DDIs.txt	verapamil	theophylline	59	59	true	positive	7.21 Theophylline    Verapamil may inhibit the clearance and increase the plasma levels of theophylline.
181-PK-DDIs.txt	vindesine	paclitaxel	32	33	true	positive	The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.  Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.
68-PK-DDIs.txt	bisoprolol fumarate	cimetidine	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.
68-PK-DDIs.txt	bisoprolol fumarate	rifampin	1	1	true	positive	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.
68-PK-DDIs.txt	bisoprolol fumarate	thiazide	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.
68-PK-DDIs.txt	bisoprolol fumarate	warfarin	4	4	true	negative	There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin.
68-PK-DDIs.txt	rifampin	cimetidine	1	3	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.
68-PK-DDIs.txt	thiazide	rifampin	3	1	true	negative	Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life.  However, initial dose modification is generally not necessary.  Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine.
68-PK-DDIs.txt	warfarin	prothrombin	4	4	true	negative	There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin.
149-PK-DDIs.txt	felbamate	felbatol	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.
149-PK-DDIs.txt	felbamate	valproate	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.
149-PK-DDIs.txt	valproate	felbatol	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.
149-PK-DDIs.txt	valproate	valproate	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.
28-PK-DDIs.txt	fluconazole	aminophylline	1	1	true	negative	The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.
28-PK-DDIs.txt	fluconazole	theophylline	1	1	true	negative	The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.
28-PK-DDIs.txt	theophylline	aminophylline	1	1	true	negative	The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers.
134-PK-DDIs.txt	propranolol	chlorpromazine	1	1	true	positive	Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.
6-PK-DDIs.txt	basis	venlafaxine	12	10	true	positive	Absorption and Distribution    Venlafaxine is well absorbed and extensively metabolized in the liver.  ODV is the only major active metabolite.  On the basis of mass balance studies, at least 92% of a single oral dose of venlafaxine is absorbed.
6-PK-DDIs.txt	venlafaxine hydrochloride	odv	17	17	true	positive	Administration of venlafaxine hydrochloride extended-release capsules (150 mg q24 hours) generally resulted in lower Cmax (150 ng/mL for venlafaxine and 260 ng/mL for ODV) and later Tmax(5.5 hours for venlafaxine and 9 hours for ODV) than for immediate release venlafaxine tablets (Cmax's for immediate release 75 mg q12 hours were 225 ng/mL for venlafaxine and 290 ng/mL for ODV; Tmax's were 2 hours for venlafaxine and 3 hours for ODV).
6-PK-DDIs.txt	venlafaxine hydrochloride	venlafaxine	17	17	true	positive	Administration of venlafaxine hydrochloride extended-release capsules (150 mg q24 hours) generally resulted in lower Cmax (150 ng/mL for venlafaxine and 260 ng/mL for ODV) and later Tmax(5.5 hours for venlafaxine and 9 hours for ODV) than for immediate release venlafaxine tablets (Cmax's for immediate release 75 mg q12 hours were 225 ng/mL for venlafaxine and 290 ng/mL for ODV; Tmax's were 2 hours for venlafaxine and 3 hours for ODV).
6-PK-DDIs.txt	venlafaxine hydrochloride	venlafaxine hydrochloride	17	17	true	positive	Administration of venlafaxine hydrochloride extended-release capsules (150 mg q24 hours) generally resulted in lower Cmax (150 ng/mL for venlafaxine and 260 ng/mL for ODV) and later Tmax(5.5 hours for venlafaxine and 9 hours for ODV) than for immediate release venlafaxine tablets (Cmax's for immediate release 75 mg q12 hours were 225 ng/mL for venlafaxine and 290 ng/mL for ODV; Tmax's were 2 hours for venlafaxine and 3 hours for ODV).
58-PK-DDIs.txt	zonisamide	zonisamide	1	1	true	positive	Zonisamide has been administered to 1,598 individuals during all clinical trials, only some of which were placebo-controlled.
80-PK-DDIs.txt	citalopram	ketoconazole	1	1	true	positive	Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
97-PK-DDIs.txt	alprazolam	cimetidine	1	1	true	positive	Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%.
131-PK-DDIs.txt	cholestyramine	colestipol	1	1	true	positive	Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.
131-PK-DDIs.txt	cholestyramine	propranolol	1	1	true	positive	Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.
131-PK-DDIs.txt	colestipol	propranolol	1	1	true	positive	Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.
172-PK-DDIs.txt	atorvastatin	atorvastatin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	atorvastatin	cyclosporine	17	15	true	positive	In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	atorvastatin	efavirenz	17	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	atorvastatin	lopinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	atorvastatin	p450	17	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	atorvastatin	ritonavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	clarithromycin	lopinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	clarithromycin	ritonavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	cyclosporine	efavirenz	14	16	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
172-PK-DDIs.txt	digoxin	atorvastatin	19	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.
172-PK-DDIs.txt	digoxin	efavirenz	18	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.
172-PK-DDIs.txt	digoxin	p450	18	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.
172-PK-DDIs.txt	efavirenz	atorvastatin	16	17	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	ethinyl estradiol	digoxin	20	19	true	positive	Patients taking digoxin should be monitored appropriately.  7.6 Oral Contraceptives    Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	ethinyl estradiol	lipitor	20	18	true	positive	7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.  7.6 Oral Contraceptives    Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	ethinyl estradiol	norethindrone	20	20	true	positive	7.6 Oral Contraceptives    Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	grapefruit	atorvastatin	11	9	true	positive	Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].  Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  7.2 Grapefruit Juice    Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
172-PK-DDIs.txt	itraconazole	grapefruit	9	11	true	positive	Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].  Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  7.2 Grapefruit Juice    Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
172-PK-DDIs.txt	itraconazole	lopinavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	itraconazole	ritonavir	9	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	lipitor	atorvastatin	2	3	true	positive	7.1 Strong Inhibitors of CYP 3A4    LIPITOR is metabolized by cytochrome P450 3A4.  Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin.
172-PK-DDIs.txt	lipitor	digoxin	17	19	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.
172-PK-DDIs.txt	lipitor	efavirenz	14	16	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
172-PK-DDIs.txt	lipitor	grapefruit	9	11	true	positive	Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].  Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  7.2 Grapefruit Juice    Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
172-PK-DDIs.txt	lipitor	lopinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	lipitor	norethindrone	18	20	true	positive	7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.  7.6 Oral Contraceptives    Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	lipitor	rifampin	14	16	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
172-PK-DDIs.txt	lipitor	ritonavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	lipitor	saquinavir	5	7	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	norethindrone	digoxin	20	19	true	positive	Patients taking digoxin should be monitored appropriately.  7.6 Oral Contraceptives    Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	p450	atorvastatin	16	17	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	p450	cyclosporine	16	14	true	positive	Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
172-PK-DDIs.txt	p450	digoxin	16	18	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.
172-PK-DDIs.txt	p450	efavirenz	16	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
172-PK-DDIs.txt	rifampin	atorvastatin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	rifampin	cyclosporine	17	15	true	positive	In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].  7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	rifampin	digoxin	17	19	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  7.5 Digoxin    When multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.  Patients taking digoxin should be monitored appropriately.
172-PK-DDIs.txt	rifampin	efavirenz	17	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	rifampin	p450	17	16	true	positive	7.4 Rifampin or other Inducers of Cytochrome P450 3A4    Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.  Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	rifampin	rifampin	17	17	true	positive	Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
172-PK-DDIs.txt	ritonavir	atorvastatin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	ritonavir	clarithromycin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	ritonavir	lopinavir	7	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	saquinavir	atorvastatin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	saquinavir	clarithromycin	7	5	true	positive	Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	saquinavir	itraconazole	7	9	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].  Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].  Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	saquinavir	lopinavir	7	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
172-PK-DDIs.txt	saquinavir	ritonavir	7	7	true	positive	Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].
150-PK-DDIs.txt	felbamate	phenobarbital	1	1	true	positive	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.
150-PK-DDIs.txt	phenobarbital	phenobarbital	1	1	true	positive	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.
187-PK-DDIs.txt	dapsone	reyataz	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	desipramine	metoprolol	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	fluvastatin	reyataz	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	nortriptyline	metoprolol	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	nortriptyline	reyataz	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	paclitaxel	reyataz	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).
187-PK-DDIs.txt	pravastatin	reyataz	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	repaglinide	reyataz	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).
187-PK-DDIs.txt	reyataz	azithromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	reyataz	desipramine	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	reyataz	erythromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).
187-PK-DDIs.txt	ritonavir	paclitaxel	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).
187-PK-DDIs.txt	ritonavir	repaglinide	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).
127-PK-DDIs.txt	norverapamil	propranolol	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.
127-PK-DDIs.txt	propranolol	propranolol	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.
127-PK-DDIs.txt	verapamil	norverapamil	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.
127-PK-DDIs.txt	verapamil	propranolol	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.
127-PK-DDIs.txt	verapamil	verapamil	1	1	true	negative	Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.
54-PK-DDIs.txt	diltiazem	diltiazem	1	1	true	positive	Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.
54-PK-DDIs.txt	diltiazem	quinidine	1	1	true	positive	Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.
100-PK-DDIs.txt	alprazolam	carbamazepine	1	1	true	positive	Drugs demonstrated to be inducers of CYP3A     Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam.
35-PK-DDIs.txt	magnesium trisilicate	nitrofurantoin	1	1	true	positive	Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
22-PK-DDIs.txt	fluconazole	ethinyl estradiol	1	2	true	negative	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.  There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.
22-PK-DDIs.txt	fluconazole	levonorgestrel	1	2	true	negative	Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women.  There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.
22-PK-DDIs.txt	levonorgestrel	ethinyl estradiol	2	2	true	negative	There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.
88-PK-DDIs.txt	septra	phenytoin	1	1	true	positive	SEPTRA may inhibit the hepatic metabolism of phenytoin.
15-PK-DDIs.txt	phenytoin	sertraline	1	1	true	negative	Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.
25-PK-DDIs.txt	phenytoin	fluconazole	1	1	true	positive	Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.
25-PK-DDIs.txt	phenytoin	phenytoin	1	1	true	positive	Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers.
155-PK-DDIs.txt	alcohol	sildenafil	80	78	true	negative	Antacids    Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.  Aspirin    Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).  Alcohol    Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.
155-PK-DDIs.txt	aspirin	alcohol	79	80	true	negative	Aspirin    Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).  Alcohol    Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.
155-PK-DDIs.txt	aspirin	aspirin	79	79	true	negative	Aspirin    Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).
155-PK-DDIs.txt	aspirin	sildenafil	79	77	true	negative	Atorvastatin    Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.  Antacids    Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.  Aspirin    Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).
155-PK-DDIs.txt	atorvastatin	aspirin	77	79	true	negative	Atorvastatin    Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.  Antacids    Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.  Aspirin    Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).
155-PK-DDIs.txt	atorvastatin	atorvastatin	77	77	true	negative	Atorvastatin    Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.
155-PK-DDIs.txt	atorvastatin	levonorgestrel	77	76	true	negative	Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).  Atorvastatin    Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.
155-PK-DDIs.txt	bosentan	bosentan	65	65	true	positive	Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	bosentan	revatio	65	64	true	positive	REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.  Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	epoprostenol	epoprostenol	69	69	true	positive	Epoprostenol    The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.
155-PK-DDIs.txt	epoprostenol	sildenafil	69	68	true	positive	Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.  Epoprostenol    The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.
155-PK-DDIs.txt	erythromycin	cimetidine	62	61	true	positive	Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.  When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
155-PK-DDIs.txt	ethinyl estradiol	atorvastatin	76	77	true	negative	Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).  Atorvastatin    Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.
155-PK-DDIs.txt	ethinyl estradiol	levonorgestrel	76	76	true	negative	Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).
155-PK-DDIs.txt	ethinyl estradiol	sildenafil	76	76	true	negative	Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).
155-PK-DDIs.txt	p450	bosentan	65	65	true	positive	Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	revatio	bosentan	64	65	true	positive	REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.  Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	revatio	erythromycin	64	62	true	positive	When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).  In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.  REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.
155-PK-DDIs.txt	revatio	p450	64	65	true	positive	REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.  Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	revatio	ritonavir	57	56	true	positive	This is consistent with ritonavir's marked effects on a broad range of P450 substrates.  Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.
155-PK-DDIs.txt	revatio	sildenafil	64	63	true	positive	In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.  REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.
155-PK-DDIs.txt	ritonavir	p450	54	53	true	positive	Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 >150 µM).  Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.
155-PK-DDIs.txt	ritonavir	ritonavir	54	54	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.
155-PK-DDIs.txt	ritonavir	sildenafil	54	55	true	positive	Ritonavir and other CYP3A Inhibitors    In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.  At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone.
155-PK-DDIs.txt	saquinavir	bosentan	63	65	true	positive	In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.  REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.  Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	saquinavir	cimetidine	63	61	true	positive	Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.  When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).  In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.
155-PK-DDIs.txt	saquinavir	erythromycin	63	62	true	positive	When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).  In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.
155-PK-DDIs.txt	saquinavir	p450	57	56	true	positive	This is consistent with ritonavir's marked effects on a broad range of P450 substrates.  Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.
155-PK-DDIs.txt	saquinavir	revatio	57	57	true	positive	Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.
155-PK-DDIs.txt	saquinavir	ritonavir	57	56	true	positive	This is consistent with ritonavir's marked effects on a broad range of P450 substrates.  Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.
155-PK-DDIs.txt	saquinavir	sildenafil	57	55	true	positive	At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone.  This is consistent with ritonavir's marked effects on a broad range of P450 substrates.  Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.
155-PK-DDIs.txt	sildenafil	atorvastatin	76	77	true	negative	Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).  Atorvastatin    Concomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.
155-PK-DDIs.txt	sildenafil	bosentan	63	65	true	positive	In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.  REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.  Bosentan    In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.
155-PK-DDIs.txt	sildenafil	epoprostenol	68	69	true	positive	Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil.  Epoprostenol    The mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.
155-PK-DDIs.txt	sildenafil	erythromycin	63	62	true	positive	When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).  In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.
155-PK-DDIs.txt	sildenafil	levonorgestrel	76	76	true	negative	Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).
2-PK-DDIs.txt	didanosine	thymidine	50	50	true	positive	In data from clinical studies, the presence of thymidine analogue mutations (M41L, D67N, L210W, T215Y, K219Q) has been shown to decrease the response to didanosine.
2-PK-DDIs.txt	thymidine	didanosine	50	50	true	positive	In data from clinical studies, the presence of thymidine analogue mutations (M41L, D67N, L210W, T215Y, K219Q) has been shown to decrease the response to didanosine.
200-PK-DDIs.txt	rifampin	methadone	1	1	true	positive	Rifampin    In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.
200-PK-DDIs.txt	rifampin	rifampin	1	1	true	positive	Rifampin    In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.
12-PK-DDIs.txt	desmethyldiazepam	sertraline	2	1	true	positive	In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03).  There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p < 0.03).
12-PK-DDIs.txt	diazepam	sertraline	1	1	true	positive	In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03).
49-PK-DDIs.txt	lithium carbonate	paroxetine	1	1	true	positive	A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.
49-PK-DDIs.txt	lithium carbonate	paroxetine hydrochloride	1	1	true	positive	A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.
49-PK-DDIs.txt	paroxetine	paroxetine hydrochloride	1	1	true	positive	A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.
7-PK-DDIs.txt	9-hydroxyrisperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.
7-PK-DDIs.txt	9-hydroxyrisperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.
7-PK-DDIs.txt	amitriptyline	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.
7-PK-DDIs.txt	amitriptyline	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.
7-PK-DDIs.txt	amitriptyline	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	carbamazepine	carbamazepine	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.
7-PK-DDIs.txt	carbamazepine	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.
7-PK-DDIs.txt	cimetidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	cimetidine	amitriptyline	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	cimetidine	cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	cimetidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	cimetidine	risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	clozapine	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.
7-PK-DDIs.txt	clozapine	cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.
7-PK-DDIs.txt	clozapine	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).
7-PK-DDIs.txt	digoxin	digoxin	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.
7-PK-DDIs.txt	digoxin	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.
7-PK-DDIs.txt	dopamine	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.
7-PK-DDIs.txt	dopamine	amitriptyline	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.
7-PK-DDIs.txt	dopamine	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	dopamine	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	fluoxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.
7-PK-DDIs.txt	fluoxetine	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.
7-PK-DDIs.txt	fluoxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.
7-PK-DDIs.txt	levodopa	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	paroxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.
7-PK-DDIs.txt	paroxetine	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.
7-PK-DDIs.txt	paroxetine	paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.
7-PK-DDIs.txt	ranitidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	ranitidine	cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	ranitidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.
7-PK-DDIs.txt	ranitidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	ranitidine	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	risperidone	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	risperidone	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.
7-PK-DDIs.txt	risperidone	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.
7-PK-DDIs.txt	risperidone	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.
7-PK-DDIs.txt	risperidone	paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.
7-PK-DDIs.txt	risperidone	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.
7-PK-DDIs.txt	valproate	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].
7-PK-DDIs.txt	valproate	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).
7-PK-DDIs.txt	valproate	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.
7-PK-DDIs.txt	valproate	risperidone	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).
7-PK-DDIs.txt	valproate	valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).
112-PK-DDIs.txt	nifedipine	clopidogrel	1	1	true	negative	Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidrogrel was coadministered with nifedipine.
53-PK-DDIs.txt	quinidine	ketoconazole	1	1	true	positive	Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.
53-PK-DDIs.txt	quinidine	p450	1	1	true	positive	Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.
63-PK-DDIs.txt	cimetidine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.
63-PK-DDIs.txt	nisoldipine	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
63-PK-DDIs.txt	nisoldipine	cimetidine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
63-PK-DDIs.txt	nisoldipine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.
63-PK-DDIs.txt	nisoldipine	nisoldipine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
63-PK-DDIs.txt	phenytoin	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
63-PK-DDIs.txt	phenytoin	nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
63-PK-DDIs.txt	phenytoin	propranolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
63-PK-DDIs.txt	propranolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
63-PK-DDIs.txt	quinidine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
63-PK-DDIs.txt	quinidine	propranolol	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
63-PK-DDIs.txt	quinidine	quinidine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
63-PK-DDIs.txt	ranitidine	cimetidine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).
63-PK-DDIs.txt	ranitidine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.
63-PK-DDIs.txt	ranitidine	nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).
113-PK-DDIs.txt	cimetidine	cimetidine	1	1	true	negative	Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine.
113-PK-DDIs.txt	nifedipine	cimetidine	1	1	true	negative	Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine.
65-PK-DDIs.txt	triazolam	nefazodone	1	1	true	positive	When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold.
30-PK-DDIs.txt	glipizide	fluconazole	1	1	true	positive	The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased following the administration of fluconazole in 13 normal male volunteers.
91-PK-DDIs.txt	atomoxetine	fluoxetine	8	9	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.
91-PK-DDIs.txt	atomoxetine hydrochloride	atomoxetine	17	17	true	positive	Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours.
91-PK-DDIs.txt	atomoxetine hydrochloride	atomoxetine hydrochloride	17	17	true	positive	Administration of atomoxetine hydrochloride with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower Cmax, and delayed Tmax by 3 hours.
91-PK-DDIs.txt	fluoxetine	atomoxetine	9	8	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.
91-PK-DDIs.txt	fluoxetine	atomoxetine hydrochloride	26	26	true	positive	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].
91-PK-DDIs.txt	paroxetine	atomoxetine	9	8	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.
91-PK-DDIs.txt	paroxetine	atomoxetine hydrochloride	26	26	true	positive	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].
91-PK-DDIs.txt	quinidine	atomoxetine	9	8	true	positive	These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].  Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.
91-PK-DDIs.txt	quinidine	atomoxetine hydrochloride	26	26	true	positive	Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)].
184-PK-DDIs.txt	amoxicillin	methotrexate	106	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.  While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.  Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.
184-PK-DDIs.txt	gastrin	nitrosamine	24	23	true	positive	No significant increase in nitrosamine concentrations was observed.  Serum Gastrin Effects    In over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole.
184-PK-DDIs.txt	methotrexate	amoxicillin	104	106	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.  While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.  Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.
184-PK-DDIs.txt	methotrexate	methotrexate	104	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	methotrexate	prothrombin	104	102	true	negative	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	naproxen	amoxicillin	104	106	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.  While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.  Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.
184-PK-DDIs.txt	naproxen	methotrexate	104	104	true	negative	Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	omeprazole	amoxicillin	107	106	true	positive	Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.  Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
184-PK-DDIs.txt	prothrombin	methotrexate	102	104	true	negative	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	prothrombin	naproxen	102	104	true	negative	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	prothrombin	warfarin	102	103	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
184-PK-DDIs.txt	warfarin	methotrexate	103	104	true	negative	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	warfarin	naproxen	103	104	true	negative	Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.  Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
184-PK-DDIs.txt	warfarin	prothrombin	103	102	true	positive	Increases in INR and prothrombin time may lead to abnormal bleeding and even death.  Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
48-PK-DDIs.txt	paroxetine	terfenadine	1	1	true	negative	An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.
177-PK-DDIs.txt	cimetidine	p450	3	1	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	diazepam	cimetidine	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	diazepam	fluoxetine	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	diazepam	fluvoxamine	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	diazepam	ketoconazole	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	diazepam	omeprazole	1	3	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	diazepam	p450	1	1	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).
177-PK-DDIs.txt	fluoxetine	p450	3	1	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	fluvoxamine	p450	3	1	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	ketoconazole	p450	3	1	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
177-PK-DDIs.txt	omeprazole	p450	3	1	true	positive	There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).  Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.  At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.
139-PK-DDIs.txt	fexofenadine	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.
139-PK-DDIs.txt	fexofenadine hydrochloride	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.
139-PK-DDIs.txt	fexofenadine hydrochloride	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.
139-PK-DDIs.txt	ketoconazole	fexofenadine	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.
139-PK-DDIs.txt	maalox	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.
139-PK-DDIs.txt	maalox	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.
116-PK-DDIs.txt	nifedipine	rosiglitazone	1	1	true	negative	Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.
116-PK-DDIs.txt	rosiglitazone	rosiglitazone	1	1	true	negative	Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.
158-PK-DDIs.txt	fluvoxamine	mexiletine	2	1	true	positive	Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.  In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.
158-PK-DDIs.txt	fluvoxamine	propafenone	2	3	true	negative	In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.  In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.
158-PK-DDIs.txt	propafenone	mexiletine	3	1	true	negative	Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.  In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.  In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.
85-PK-DDIs.txt	fluvoxamine	tacrine	1	1	true	positive	In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.
203-PK-DDIs.txt	desipramine	desipramine	1	1	true	positive	Desipramine    Blood levels of desipramine have increased with concurrent methadone administration.
203-PK-DDIs.txt	desipramine	methadone	1	1	true	positive	Desipramine    Blood levels of desipramine have increased with concurrent methadone administration.
111-PK-DDIs.txt	doxazosin	doxazosin	1	1	true	positive	Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.
111-PK-DDIs.txt	nifedipine	doxazosin	1	1	true	positive	Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.
125-PK-DDIs.txt	quinidine	propranolol	1	1	true	positive	The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.
45-PK-DDIs.txt	paroxetine	p450	2	1	true	positive	Phenobarbital induces many cytochrome P450 (oxidative) enzymes.  When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.
45-PK-DDIs.txt	paroxetine	phenobarbital	2	1	true	positive	Phenobarbital induces many cytochrome P450 (oxidative) enzymes.  When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.
191-PK-DDIs.txt	itraconazole	fluvastatin	1	1	true	negative	Itraconazole:    Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.
191-PK-DDIs.txt	itraconazole	itraconazole	1	1	true	negative	Itraconazole:    Concomitant administration of fluvastatin (40 mg) and itraconazole (100 mg daily x 4 days) does not affect plasma itraconazole or fluvastatin levels.
159-PK-DDIs.txt	digoxin	mexiletine	1	1	true	negative	Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.
159-PK-DDIs.txt	digoxin	mexiletine hydrochloride	1	1	true	negative	Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.
73-PK-DDIs.txt	noroxycodone	rifampin	53	55	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.
73-PK-DDIs.txt	noroxycodone	voriconazole	53	54	true	positive	Drug-Drug Interactions    CYP3A4 Inhibitors  CYP3A4 is the major enzyme involved in noroxycodone formation.  A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.
73-PK-DDIs.txt	oxycodone	p450	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.
73-PK-DDIs.txt	oxycodone	rifampin	55	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.
73-PK-DDIs.txt	oxycodone	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.
73-PK-DDIs.txt	oxymorphone	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.
73-PK-DDIs.txt	oxymorphone	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.
73-PK-DDIs.txt	p450	rifampin	56	55	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.
73-PK-DDIs.txt	p450	voriconazole	56	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.
73-PK-DDIs.txt	rifampin	oxymorphone	55	56	true	positive	CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.  CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.
73-PK-DDIs.txt	rifampin	voriconazole	55	54	true	positive	A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively.  CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively.
73-PK-DDIs.txt	thyroid stimulating hormone	acth	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
73-PK-DDIs.txt	thyroid stimulating hormone	cortisol	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
73-PK-DDIs.txt	thyroid stimulating hormone	lh	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
73-PK-DDIs.txt	thyroid stimulating hormone	luteinizing hormone	23	21	true	positive	Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans.  They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs.  Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
83-PK-DDIs.txt	theophylline	tacrine	1	1	true	positive	Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold.
107-PK-DDIs.txt	metoprolol succinate	metoprolol	33	31	true	positive	Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%.  The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects.  Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.
106-PK-DDIs.txt	clonidine	metoprolol	7	5	true	positive	In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol.  These increases in plasma concentration would decrease the cardioselectivity of metoprolol.  7.3 Digitalis, Clonidine, and Calcium Channel Blockers    Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate.
78-PK-DDIs.txt	citalopram	pimozide	1	1	true	positive	In a controlled study, a single dose of pimozide 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
163-PK-DDIs.txt	acyclovir	acyclovir	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.
163-PK-DDIs.txt	meperidine	acyclovir	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.
163-PK-DDIs.txt	meperidine	normeperidine	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.
163-PK-DDIs.txt	normeperidine	acyclovir	1	1	true	positive	Acyclovir    Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.
44-PK-DDIs.txt	paroxetine	paroxetine hydrochloride	1	1	true	positive	In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.
44-PK-DDIs.txt	paroxetine	pimozide	1	1	true	positive	In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.
44-PK-DDIs.txt	paroxetine hydrochloride	paroxetine hydrochloride	1	1	true	positive	In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.
44-PK-DDIs.txt	paroxetine hydrochloride	pimozide	1	1	true	positive	In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.
98-PK-DDIs.txt	alprazolam	desipramine	1	1	true	positive	The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
98-PK-DDIs.txt	alprazolam	imipramine	1	1	true	positive	The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
98-PK-DDIs.txt	desipramine	imipramine	1	1	true	positive	The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
17-PK-DDIs.txt	sertraline	sertraline	1	1	true	positive	In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.
17-PK-DDIs.txt	tolbutamide	sertraline	1	1	true	positive	In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.
47-PK-DDIs.txt	9-hydroxyrisperidone	desipramine	6	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.
47-PK-DDIs.txt	9-hydroxyrisperidone	risperidone	6	5	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.
47-PK-DDIs.txt	paroxetine	9-hydroxyrisperidone	4	6	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.
47-PK-DDIs.txt	paroxetine	atomoxetine	5	7	true	positive	Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.  In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.  The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.
47-PK-DDIs.txt	paroxetine	desipramine	2	4	true	positive	Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.  In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.
47-PK-DDIs.txt	paroxetine	risperidone	3	5	true	positive	In most patients (>90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.  In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.
47-PK-DDIs.txt	risperidone	desipramine	5	4	true	positive	In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively.  Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.
26-PK-DDIs.txt	cyclosporine	cyclosporine	1	1	true	positive	Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.
26-PK-DDIs.txt	fluconazole	cyclosporine	1	1	true	negative	Cyclosporine AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.
51-PK-DDIs.txt	paroxetine	fosamprenavir	1	1	true	positive	Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.
51-PK-DDIs.txt	paroxetine	ritonavir	1	1	true	positive	Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.
51-PK-DDIs.txt	ritonavir	fosamprenavir	1	1	true	positive	Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.
137-PK-DDIs.txt	mcpp	carbamazepine	2	1	true	positive	Carbamazepine induces CYP3A4.  Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.
137-PK-DDIs.txt	trazodone	carbamazepine	2	1	true	positive	Carbamazepine induces CYP3A4.  Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.
137-PK-DDIs.txt	trazodone	mcpp	2	2	true	positive	Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.
66-PK-DDIs.txt	alprazolam	nefazodone hydrochloride	2	4	true	negative	Nefazodone plasma concentrations were unaffected by alprazolam.  If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended.  No dosage adjustment is required for nefazodone hydrochloride.
66-PK-DDIs.txt	nefazodone	alprazolam	1	1	true	positive	When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold.
66-PK-DDIs.txt	nefazodone	nefazodone	1	1	true	positive	When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold.
36-PK-DDIs.txt	nitrofurantoin	probenecid	1	1	true	positive	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
36-PK-DDIs.txt	sulfinpyrazone	nitrofurantoin	1	1	true	positive	Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
108-PK-DDIs.txt	nifedipine	quinidine sulfate	2	2	true	positive	Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.
108-PK-DDIs.txt	quinidine	nifedipine	1	2	true	positive	Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro.  Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.
108-PK-DDIs.txt	quinidine	quinidine sulfate	1	2	true	positive	Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro.  Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.
1-PK-DDIs.txt	didanosine	tenofovir disoproxil fumarate	3	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].
46-PK-DDIs.txt	phenytoin	paroxetine	1	1	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.
46-PK-DDIs.txt	phenytoin	paroxetine hydrochloride	2	4	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).
199-PK-DDIs.txt	zidovudine	methadone	1	1	true	positive	Zidovudine    Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.
199-PK-DDIs.txt	zidovudine	zidovudine	1	1	true	positive	Zidovudine    Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.
75-PK-DDIs.txt	cholecystokinin	secretin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	cholecystokinin	testosterone	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	cortisol	cholecystokinin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	cortisol	secretin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	cortisol	testosterone	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	estradiol	cholecystokinin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	estradiol	cortisol	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	estradiol	omeprazole	21	19	true	negative	[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.  Other Effects    Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.  Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	estradiol	secretin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	estradiol	testosterone	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	omeprazole	cholecystokinin	19	21	true	negative	[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.  Other Effects    Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.  Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	omeprazole	cortisol	19	21	true	negative	[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.  Other Effects    Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.  Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	omeprazole	creatinine	69	69	true	positive	Renal Impairment    In patients with chronic renal impairment, whose creatinine clearance ranged between 10 and 62 mL/min/1.73 m2, the disposition of omeprazole was very similar to that in healthy volunteers, although there was a slight increase in bioavailability.
75-PK-DDIs.txt	omeprazole	secretin	19	21	true	negative	[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.  Other Effects    Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.  Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	omeprazole	testosterone	19	21	true	negative	[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.  Other Effects    Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.  Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	prolactin	cholecystokinin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	prolactin	cortisol	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	prolactin	estradiol	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	prolactin	omeprazole	21	19	true	negative	[See Clinical Pharmacology (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.  Other Effects    Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.  Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	prolactin	secretin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	prolactin	testosterone	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
75-PK-DDIs.txt	testosterone	secretin	21	21	true	negative	Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
126-PK-DDIs.txt	nifedipine	propranolol	1	1	true	positive	The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.
130-PK-DDIs.txt	propranolol	metoclopramide	1	1	true	negative	Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics.
77-PK-DDIs.txt	citalopram	digoxin	1	1	true	negative	In subjects who had received 21 days of 40 mg/day citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
186-PK-DDIs.txt	cyclosporine	creatinine	21	20	true	positive	Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.
186-PK-DDIs.txt	cyclosporine	simvastatin	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.
133-PK-DDIs.txt	mesoridazine	propranolol	1	1	true	positive	Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.
133-PK-DDIs.txt	thioridazine	mesoridazine	1	1	true	positive	Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.
133-PK-DDIs.txt	thioridazine	propranolol	1	1	true	positive	Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.
